FDA Updates for Week of April 4, 2022
April 9th 2022The FDA approves novel therapy for schizophrenia and bipolar and grants accelerated approval to treat rare disorder. The agency also accepted the sBLA and has granted priority review for Actemra or the treatment of COVID-19 and has extended the PDUFA date for vutrisiran.
Read More
Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?
April 7th 2022Marcus Snow, MD, , chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.
Read More
Briana Contreras, editor of Managed Healthcare Executive spoke with Emad Rizk, M.D., chairman, president, and CEO of Cotiviti in this week's episode of Tuning In to the C-Suite. In the discussion, they talked about the issues of risk in healthcare and how they have led to inequalities in care. They also addressed how adopting risk assessment tools that expand access to data around social determinants of health can help reduce bias and improve care.
Listen
Biosimilars Are Supposed to Save Money. Providence St. Joseph Health Has Made That Happen.
April 6th 2022Using an aggressive utilization management approach, Providence St. Joseph Health directed physicians toward the use of biosimilars immediately after they came to market, saving nearly $27 million over two years in the process, according to Sophia Z. Humphreys, Pharm.D., M.H.A., the healthcare system’s director of system pharmacy clinical Services.
Read More
FDA Updates Week of March 28, 2022
April 2nd 2022The FDA authorizes second COVID-19 booster and approves a higher does of Ozempic, Cabenuva for adolescents with HIV, a therapy for rare seizer disorder, and an oral testosterone replacement. The agency issues a complete response letter for a therapy for anemia related to chronic kidney disease, and an advisor committee votes down a drug for ALS.
Read More
AMCP 2022: Soumya Vishwanath of Magellan Rx Management Addresses Digital Therapeutics at AMCP 2022
March 31st 2022Soumya Vishwanath, PharmD, senior manager of Formulary Strategy at Magellan Rx Management, talked about digital therapeutics in the behavioral health space and formulary strategy space during the annual AMCP 2022 conference in Chicago.
Watch
“Popping a pill” makes cancer treatment more convenient, but research presented at the AMCP annual meetings shows that almost half of cancer patients on oral therapies are nonadherent. Oral administration typically moves a drug to the pharmacy benefit, which can mean high out-of-pocket costs and, in turn, nonadherence.
Read More